Financial writer advises caution on Jyong Biotech Ltd. IPO due to high debt, legal issues, and FDA challenges. Click for my ...

Speaking this week at BIO CEO, the heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public ...

A look at the M&A and stock market pictures for full-year 2024—and the potential strategic implications for pharma and ...

Aardvark’s lead candidate ARD-101 is being investigated in a Phase III study for hyperphagia in Prader-Willi syndrome.

Proceeds will support testing of drugs designed to suppress hunger in people with the tough-to-treat rare disease and, ...

Two sizable companies and a handful of small Asian issuers were listed in the US this past week. Read more here.

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...

Cornerstone Research recently issued its 2024 Year in Review report examining recent trends in securities class action filings. For the second year ...

Kestra Medical Technologies, a Kirkland, Wash.-based company selling cardiac monitoring and therapeutic devices, filed for an ...

There were only 36 biotech IPOs last year, compared with 68 in 2015 and a record 85 in 2014 – and a rebound was expected in 2017. Are biotech IPOs back in fashion? | pharmaphorum Skip to main ...

After hitting a record high in 2021, the number of biotech IPOs have fallen to a yearly average in the 20s, with most successful entries in the last few quarters involving companies with mid- to ...